H3 Biomedicine Preclinical Studies Show Selective Estrogen Receptor Covalent Antagonist Inactivates Wild-type and Mutant Estrogen Receptor Alphas.
M2 PHARMA-December 8, 2017-H3 Biomedicine Preclinical Studies Show Selective Estrogen Receptor Covalent Antagonist Inactivates Wild-type and Mutant Estrogen Receptor Alphas
(C)2017 M2 COMMUNICATIONS
- Cambridge, Massachusetts-based oncology treatments specialist H3 Biomedicine Inc. scientists have presented data from preclinical studies involving H3B-6545, an oral, selective small molecule covalent antagonist of wild-type and mutant estrogen receptor (ER) in a poster session at the San Antonio Breast Cancer Symposium (SABCS) annual meeting, the company said.
The poster presented at SABCS demonstrated that H3B-6545 has a unique mode of estrogen receptor alpha (ER?) antagonism and exhibits superior preclinical anti-tumor activity to fulvestrant in the MCF-7 xenograft model with once daily oral dosing, achieving maximal antitumor activity at doses >10x below the maximum tolerated dose in mice.
In addition, H3B-6545 demonstrated superior preclinical anti-tumor activity to both tamoxifen and fulvestrant in patient derived xenograft models of breast cancer carrying estrogen receptor mutations.
Based on these results, in September, 2017, H3B-6545 entered into a Phase 1 multi-center, open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the compound in women with ER-positive, Her2-negative metastatic breast cancer.
H3B-6545 is an orally bioavailable, potent and selective small molecule modulator of wild-type and mutant estrogen receptor. Scientists at H3 Biomedicine have discovered a new class of ER? antagonists called Selective Estrogen Receptor Covalent Antagonists (SERCAs) that inactivate the estrogen receptor by targeting a cysteine that is not present in other nuclear hormone receptors.
SERCAs have a unique biological and activity profile compared to Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs).
Initial clinical development of H3B-6545 will target breast cancer patients with wild-type and mutant ER? and will assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of H3B-6545.
H3 Biomedicine, a member of Eisai's global Oncology Business Group established as a subsidiary of Eisai's US pharmaceutical operation Eisai Inc., specializes in the discovery and development of precision oncology treatments.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 8, 2017|
|Previous Article:||Data Review by IDMC Recommends Continuation of CEL-SCI Phase 3 Immunotherapy Study in Head and Neck Cancer Patients.|
|Next Article:||Aveo Oncology Completes Enrollment in Tivozanib Trial in RCC, Initiates Studies of Ficlatuzumab in HNSCC and Pancreatic Cancer.|